

Ellen Dittberner returns as CFO at AroCell on January 13, 2025

AroCell AB is pleased to announce that Ellen Dittberner will return to her role as Chief Financial Officer (CFO) on January 13, 2025, after being on parental leave since February 2024. Ellen, who has previously played an important role in AroCell's financial development and strategic success, is now ready to resume her work and lead the company's financial function forward.

During Ellen's parental leave, Lars Jakobsson has served as Acting CFO. Lars, with his extensive experience from both AroCell and IDL Biotech, has been an invaluable resource during this period. We thank him for his efforts and commitment.

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Attachments

[Ellen Dittberner returns as CFO at AroCell on January 13, 2025](#)